Safe harbor Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the advancement, timing and sufficiency of our clinical trials, patient enrollments in our existing and planned clinical trials and the timing thereof, the results of our clinical trials, the timing and release of our clinical data, statements regarding our expectations about our cash runway, our goals to develop and commercialize our product candidates, our expectations regarding the size of the patient populations for our product candidates if approved for commercial use and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including the impact of the SARS-COV-2 coronavirus as a global pandemic and related public health issues, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements. Igniting a Systemic Immune Response to Cancer JP Morgan January 2024

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 2 Safe harbor Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the advancement, timing and sufficiency of our clinical trials, patient enrollments in our existing and planned clinical trials and the timing thereof, the results of our clinical trials, the timing and release of our clinical data, statements regarding our expectations about our cash runway, our goals to develop and commercialize our product candidates, our expectations regarding the size of the patient populations for our product candidates if approved for commercial use and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including the impact of the SARS-COV-2 coronavirus as a global pandemic and related public health issues, the ongoing military conflict between Russia and Ukraine and the impact on the global economy and related governmental imposed sanctions, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.

© 2022 Replimune Group Inc. 3 3 • RP1 – activity across multiple skin cancers supports broad skin cancer strategy • 140 patient registrational IGNYTE study in anti-PD1 failed melanoma • ~ 1 in 3 patients demonstrating durable response • 100% of responses >6 months with median DOR >24 months • BLA filing planned 2H 2024 • 211 patient 1L CSCC randomized controlled CERPASS study; primary analysis reported December 2023 • Missed significance at P<0.025 for dual endpoints (ORR/CRR) • However, clear clinical benefit for RP1+cemiplimab was demonstrated • CRR vs. cemplimab alone (38.1% vs 25.0%, p=0.0401) • Duration of response increased • Strong data in hard-to-treat solid organ transplant patients as monotherapy • Potential for the portfolio to deliver commercial revenues beginning in late 2025 • RP2 has shown compelling monotherapy and combination activity • Uveal melanoma RCT study in planning -> potential for a rare cancer franchise • Strong balance sheet ~ $466m (1) as of 31 December 2023; runway into H2 2026 Replimune; Industry Leader in Oncolytic Immunotherapy 1Per the protocol p<0.025 is required for formal statistical success in CERPASS for CRR or ORR alone. *SOT=solid organ transplant (1) Unaudited estimate

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 4 Oncolytic immunotherapy - mechanism of action Injected tumor Distant tumors Bommareddy PK et al AJCD. 2016 Healthy tissue Tumor tissue Oncolytic immunotherapy Intact host antiviral response: Normal tissue remains undamaged Dysregulated host antiviral response allows robust virus replication and tumor lysis Attenuated potent new clinical isolate of HSV-1 modified to express a fusogenic glycoprotein and immune stimulating proteins Injected tumor 1 MECHANISM 2 MECHANISM Altering of tumor microenvironment Infection of more tumor cells Release of virus progeny Local Inflammation T cell infiltration and killing of distant, uninjected tumors Dendritic cell T cell Generating a strong and durable systemic anti-tumor immune response Immune response Tumor cell death and release of tumor antigens Enhanced T cell priming and activation

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 5 RPx positioning: Platform designed to address a range of tumor types with an optimal balance of potency & tolerability Payloads GALV-GP R-, GM-CSF GALV-GP R-, anti-CTLA-4, GM-CSF Target Immunologically responsive tumor types, including anti-PD1 failed Less immunologically responsive tumor types Intended indication(s) Skin cancers (CSCC inc. SOT*, anti-PD1 failed melanoma, anti-PD1 failed CSCC, other NMSCs, etc) Rare cancers and neo adjuvant ; uveal melanoma registration study planned Clinical activity in anti-PD1 failed patients demonstrated Good tolerability and Safety profile demonstrated Injection location Superficial, nodal & visceral Superficial, nodal & visceral Systemic activity Clear systemic effects seen in responding patients (un-injected tumor responses, responses are generally highly durable) Other design considerations Designed for more I-O sensitive tumor types with excellent safety profile alone & in combination Increased I-O systemic activity, also with excellent safety profile alone & in combination *SOT=solid organ transplant

© 2022 Replimune Group Inc. 6 AGENDA © 2023 Replimune Group Inc. RP1: Establishing a major skin cancer franchise

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 7 IGNYTE RP1 + nivolumab in anti-PD1 failed melanoma registrational study data Consistent ORR benefit across all subgroups Includes 1 patient with a unconfirmed PR (uPR). There are 5 patients still on study with the opportunity for response. Response data presented is by investigator assessment; the primary analysis from the study will be by blinded, independent central review. BOR=best overall response • 1 in 3 patients experienced a response • 26.4% ORR in hard-to-treat Ipi+Nivo failed patients (approx. 50% of the overall study population) • 100% of responses lasted >6 months, with median DOR >24 months BOR n (%) All patients (n=156) Prior cohort (n=16) Anti-PD1 failed cohort (n=140) All patients (n=156) Prior single agent anti-PD1 (n=84) Prior combination anti–PD-1 & anti– CTLA-4* (n=72) Stage IIIb/IIIc/IVa (n=76) Stage IVb/c/d (n=80) Primary resistance to anti-PD1 (n=91) Secondary resistance to anti-PD1 (n=63) CR 2 (12.5) 17 (12.1) 19 (12.2) 14 (16.7) 5 (6.9) 15 (19.7) 4 (5.0) 12 (13.2) 6 (9.5) PR 4 (25.0) 26 (18.6) 30 (19.2) 16 (19.0) 14 (19.4) 14 (18.4) 16 (20.0) 19 (20.9) 11 (17.5) SD 2 (12.5) 29 (20.7) 31 (19.9) 21 (25.0) 10 (13.9) 18 (23.7) 13 (16.3) 15 (16.5) 16 (25.4) PD 8 (50.0) 68 (48.6) 76 (48.7) 33 (39.3) 43 (59.7) 29 (38.2) 47 (58.8) 45 (49.5) 30 (47.6) ORR 6 (37.5) 43 (30.7) 49 (31.4) 30 (35.7) 19 (26.4) 29 (38.2) 20 (25.0) 31 (34.1) 17 (27.0)

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 8 Depth of response n=156 Maximum change in target lesions; patients with at least one follow up assessment Patients with at least one post baseline assessment – target lesion response for each patient Key Takeaways • Target tumor reduction is seen in >50% of patients • Responses were seen across disease stages, including complete responses in patients with stage IVM1b/c disease

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 9 Duration of response (time from baseline to end of response for responders) Probability (%) Key Takeaway Responses are highly durable, with median DOR >24 months >6 months >12 months >18 months >24 months 100% 90.5% 84.7% 79.7% All patients have at least 6 months follow up, median follow up is 88.21 weeks

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 10 Promising OS is seen across disease subsets, including those with the greatest unmet need Stage IIIb/IIIc/IVM1a vs Stage IV M1b/c/d Prior anti-CTLA-4+anti-PD1 vs prior anti-PD1 alone All patients have at least 6 months follow up, median follow up is 88.21 weeks

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 11 Patient 4401-2021: Prior Tafinlar/Mekinist, Keytruda Prior BRAF/MEK as well as progressed on anti-PD1 Stage IVM1c 12JAN2021/Baseline 15FEB2022/Day 368 12JAN2021/Baseline 15FEB2022/Day 368 Data snapshot date: 3 Nov 2022 Injected Un-injected

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 12 Patient 1121-2011: Prior Opdivo (adjuvant) and Keytruda (first line for metastatic disease), Stage IVM1c 29 JUL 2021 / Screening 20 APRIL 2022 Injected Un-injected

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 13 22 Jul 2021/ Baseline 22 Sep 2021/ Day 57 29 Dec 2021/ Day 155 Injected Un-injected Patient 1121-2011 Cont’d: Prior Opdivo (adjuvant) and Keytruda (first line for metastatic disease), Stage IVM1c

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 14 IGNYTE - Regulatory summary/next steps IGNYTE IGNYTE FDA Type C meeting on anti-PD1 failed melanoma • The FDA acknowledged that the IGNYTE population is one of unmet need • The FDA agreed with a 2-arm randomized trial design in anti-PD1 failed melanoma with physician’s choice as a comparator arm in the study population • The study should be underway at time of BLA submission • A BLA submission for anti-PD1 failed melanoma is planned for 2H 2024 pending • Centrally reviewed data by RECIST v 1.1 • All patients followed for at least 12 months (which is the per protocol primary analysis timepoint) • All responding patients followed for at least 6 months from response initiation

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 15 CSCC disease characteristics and typical patient presentation • Second most common skin cancer with ≈700,000 patients annually in the U.S.1 • Approximately 7,000-15,000 US deaths annually1-3 • 80% of patients die from locoregional progression, not metastatic disease4,5 • Usually develops from precursor lesions (actinic keratosis) but may be de novo; majority (80–90%) occur on the head and neck • CSCC is a predominately outward growing disease with large, painful, superficial tumors which can impact quality of life and contribute to social isolation • Disfiguring, painful • Foul smelling drainage • Delay in seeking medical care • Anti-Pd1 SOC ~ 50% ORR, ~ 15-25% CRR. 1Rogers et al JAMA Dermatol 10 2015; 2Clayman et al JCO 23 2005; 3Mansouri et al J Am Acad Dermatol 153 2017; 4Schmults et al JAMA Dermatol 149 2013; 5Motaparthi et al Adv Anat Pathol 24 2017

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 16 CERPASS registration-directed Ph2 study in CSCC Key Eligibility Criteria: • Locally-advanced/metastatic CSCC • ECOG PS 0 or 1 • No active autoimmune disease • No prior treatment with a PD-1/PD-L1 inhibitor • No untreated brain metastases 57 weeks treatment‡ 3-year survival follow up †First dose of RP1 to be given as monotherapy with cemiplimab to be given with second dose of RP1 ‡57 weeks treatment for the combination arm; treatment duration for cemiplimab-only arm is 54 weeks Key Endpoints • Dual independent primary endpoints: Complete Response Rate & Overall Response Rate* • Approx. 15% absolute difference in CRR and/or ORR required • Secondary endpoints: DOR, PFS, OS, disease-specific survival, safety/tolerability 2:1 N=211 RP1 IT Q3W x 8 doses† (1x106 PFU/mL for one dose followed by 1x107 PFU/mL for 7 doses) + Cemiplimab 350mg Q3W IV Cemiplimab 350mg Q3W IV *Note p≤0.05 is required if both dual primary endpoints hit for statistical success, if only one of the dual endpoint hits need a p≤0.025 is needed

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 17 Confirmed ORR & CRR (ITT population) Key Takeaways • While ORR was similar between the arms, the number of patients who achieved a CRR was substantially increased with RP1+cemiplimab (P=0.04) • In LA CSCC, there was a more than doubling of the CR rate for RP1+cemiplimab vs cemiplimab alone (48.1% vs 22.6%) • CRs are the key driver of long-term clinical benefit in CSCC BOR (confirmed response) All N=211 n/% Cemiplimab n=72 RP1+ cemiplimab n=139 PR 19 (26.4) 20 (14.4) SD 14 (19.4) 18* (12.9) PD 12 (16.7) 27 (19.4) OR 37 (51.4%) 73 (52.5%) P=0.6921 CR 18 (25.0%) 53 (38.1%) P=0.0401 *One patient shown as SD was a CR due to the confirmatory assessment happening 21 days rather than later 28 days as required per protocol (CRR if included = 38.8%; p=0.031); **&Nominal p value 0.013 BOR=best overall response 1Per the protocol p≤0.025 is required for formal statistical success in CERPASS for CRR or ORR alone and p≤0.05 if both endpoints were met BOR (confirmed response) Locally advanced CSCC n=83 Metastatic CSCC n=128 n/% Cemiplimab n=31 RP1+ cemiplimab n=52 Cemiplimab n=41 RP1+ cemiplimab n=87 OR 18 (58.1%) 33 (63.3%) 19 (46.3%) 40 (46.0%) CR 7 (22.6%) 25 (48.1%) 11 (26.6%) 28 (32.2%)

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 18 Five of the most visually impactful CRs with RP1+cemiplimab Baseline 81 weeks 4805-0002 Baseline 81 weeks 1140-0002 Baseline 63 weeks 3311-0002 Baseline 63 weeks 3002-0008 Baseline 54 weeks 1141-0009

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 19 Duration of response (immature data) Time from baseline to end of response for responders All responding patients Key Takeaway Duration of response was improved with RP1+cemiplimab as compared to cemiplimab alone (HR 0.45 immature data). While the improvement is clear in metastatic disease, locally advanced patient data is currently too immature to draw conclusions. The study will continue to allow all endpoints to further mature, in particular for DOR, PFS & OS Metastatic patients Locally advanced patients

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 20 CERPASS - next steps CERPASS • CERPASS missed its primary endpoints while demonstrating treatment effects suggesting clinical benefit • CR rate • Duration of response • All time-based endpoints are immature (DOR, PFS and OS) and will be followed to maturity • Mature data required to determine whether any filing or compendia listing strategy is warranted

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 21 Additional unmet needs in CSCC/NMSC ARTACUS STUDY • Treatment of high risk immune compromised populations who develop skin cancers • Anti-PD1 use can lead to loss of graft • RP1 monotherapy; 35% ORR (N=23) IGNYTE anti-PD1 failed NMSC • No FDA approved options for anti-PD1-failed CSCC/NMSC; ~ 70% of treated patients still ultimately progress • RP1 + nivo 30% ORR (N=30) 1Lam JKS, et al. Head Neck. 2018;40:985-992. 2Friman T, et al. Int J Cancer. 2022;150(11):1779-91. 3Marin-Acevedo et al Cancers 2023, 15(12), 3180

AGENDA © 2023 Replimune Group Inc. RP1 Commercial Opportunity

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 23 Significant opportunity to establish a broad skin cancer franchise built upon strong foundation in melanoma Future growth driver ~11K patients2 ~13K patients1 Ability to improve the SOC either as combo or as monotherapy Address high unmet need in anG-PD-1 failed seKngs Poten0al NMSC* access via compendia+ 1L prior adjuvant 2L+ BRAF WT 2L+ BRAF MT ~45K patients Improving cure rates in early-stage paGents Earlier stage skin cancers** Anti-PD1-failed melanoma 1L CSCC SOT NMSC Anti-PD1 failed Immuno-compromised (other) Neoadjuvant CSCC Neoadjuvant melanoma RP1 near-term opportunity is significant Source: 1Melanoma US treated patient population for 2030 based on CancerMPact® Patient Metrics, Cerner Enviza (available from www.cancermpact.com Accessed 15 Oct 2023), with adjustments to future 2L+ treatment rates based on primary market research. 2CSCC US treated patient population for 2030 based IQVIA claims, primary market research, and company data. *NMSC (non-melanoma skin cancers); RP1+cemiplimab or RP1+nivolumab or RP1 mono **Neoadjuvant CSCC (est. 30K patients) and melanoma (est. 15K patients). SOT=solid organ transplant “Opportunity to change the treatment paradigm and ensure all appropriate patients can benefit from RP1” ~70,000 treatable pa;ents in the US +Spontaneous use will not be promoted

© 2023 Replimune Group Inc. 24 Investment in manufacturing to support full commercialization • 63,000 square foot state-of-the-art facility for GMP manufacturing • RP1-2 technology transfer from CMO successfully completed • RP1 released to clinic post comparability analysis • RP1 BLA consistency lot runs complete • Scale expected to be sufficient to cover global commercialization of all Replimune’s product candidates at full capacity • Commercially attractive cost of goods & ‘off the shelf’ product practicality Commercial scale in-house manufacturing established

© 2022 Replimune Group Inc. 25 AGENDA © 2023 Replimune Group Inc. RP2 update

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 26 RP2 leverages Replimune’s platform to express anti-CTLA-4 • Anti-CTLA-4 prevents immune blockade at the APC / T cell interface § Anti-CTLA-4 is clinically validated; Ipilimumab, tremelimumab • RP2 has shown durable mono-therapy responses in multiple immune insensitive tumor types § Salivary gland cancer § Chordoma § Uveal melanoma § Esophogeal cancer • 30% ORR (N=17) in 2L uveal melanoma with impressive duration § Randomized control trial planned ; foundation of rare disease strategy • Rare head and neck cancers • Sarcomas • HPV associated ; vulvar, anal

© 2022 Replimune Group Inc. Confiden'al 272 7 "It’s a true miracle, there is no other word to describe it. I’ve been able to work as a builder again and spend time with my family, there’s nothing I can’t do.” “My final lifeline” Mucoepidermoid carcinoma pa.ent featured in BBC news Prior carbopla+n/paclitaxel, bicalutamide, ceralaser+b - ongoing CR>2 years (RP2 monotherapy) 1 month 4 months

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 28 Patient 4401-0029: Chordoma Prior imatinib - ongoing PR at over 8 months (RP2 monotherapy) Pt 4401-0029 - ongoing PR • Left gluteal muscle injected • Liver & >50 small lung lesions also disappeared during treatment Screening 3 months 6 months Injected Un-injected

© 2022 Replimune Group Inc. Confiden'al 292 9 Pa.ent 4401-0029: Chordoma Prior ima+nib - ongoing PR at over 8 months (RP2 monotherapy) Pt 4401-0029 - ongoing PR • Left gluteal muscle lesion injected • Liver & >50 small lung lesions also disappeared during treatment Injected Un-injected Baseline 3 months 6 months

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 30 RP2 in uveal melanoma 1Carvajal RD et al. Br J Ophthalmol 2017; 2Nathan P et al. N Engl J Med. 2021;385(13):1196-1206; 3PelsterMS et al. J Clin Oncol. 2021;39(6):599-607; 4Lukzky J et al SMR 2022; * Versus investigator’s choice, pembrolizumab, ipilimumab, or dacarbazine • Ocular or “uveal” melanoma is a rare cancer with approx. 1,000 cases in the US per year1 • Originates from melanocytes and can occur in several eye locations • The historic median OS is approx. 12 months1 • Uveal melanoma behaves quite differently from skin melanoma • Mostly metastasizes to the liver (approx. 70-90% of cases) and once this occurs only about 10% of these patients survive beyond a year • A difficult to treat tumor where CPIs have previously demonstrated limited activity2,3,4 • Kimmtrak (tebentafusp) is the 1st approved agent in uveal melanoma in HLA-A-02:01-positive adult patients (approx. 50% of the total population)* • Unmet need for uveal melanoma patients remains high, including improved efficacy/tolerability, effective options for HLA negative patients, and options for Kimmtrak and anti-PD1 failed patients

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 31 RP2 Uveal melanoma: Duration of response Durable responses in small initial dataset, both monotherapy RP2 and RP2 + nivo .. 0 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 Duration of Study (Days) 4401-0007 4402-0019 4401-0022 4401-0026 4401-0002 4402-0018 4403-0014 4401-0021 3412-0001 4403-0019 4401-0014 4401-0003 4403-0018 4403-0015 4403-0017 4402-0014 4402-0007 Subjects Death PR SD PD Best Overall Response NE PD SD PR CR Replimune Study No. RP2-001-18 Figure: Duration of Study (Ocular Melanoma: Uveal) Key Takeaways • 5/14 (29.4%) evaluable patient responders • Heavily pre-treated population, with all responders having failed prior CPI Durable responses represent compelling initial signal • Longest ongoing response over 24 months CR, complete response; NE, not evaluable; PD, progressive disease; PR, parEal response; SD, stable disease Data from SMR 2023

© 2022 Replimune Group Inc. Confiden'al 323 2 Screening 19 months Pt 201-4403-0017 – ongoing PR • Liver metastases • PaNent has ongoing PR at 19 months Uveal melanoma patient featured in ITV news Prior nivolumab+ ipilimumab – PR (RP2+nivolumab) "This trial has given me hope in the treatment, the trial, my care, and I'm happy. I don't think about dying anymore at all" ITV, 03 November 2023 Injected Un-injected

©© 2022 Replimune Group Inc. 2023 Replimune Group Inc. 33 RP1 in skin cancer Mid-stage pipeline Strong cash position • Strong balance sheet; $466m (1) as of 31 December 2023 • Cash Runway into H2 2026 • Initial snapshot of data from all 156 anti-PD1 failed melanoma patients demonstrate that RP1+nivolumab maintains transformative potential in this high unmet need setting • BLA submission planned for 2H 2024 • While CERPASSS missed its primary endpoints at P>0.025, a clinically meaningful benefit in CRR (P=0.04) and DOR in CSCC was demonstrated • Other skin cancer data in hard-to-treat settings such as solid organ transplant recipients & anti-PD1 failed melanoma & NMSC demonstrate compelling clinical activity • Strong data with RP2 in uveal melanoma • Planning for a randomized controlled pivotal study in uveal melanoma underway • Plan to investigate other rare cancer opportunities (1) Unaudited es,mate

MISSION To enable tumor directed oncolytic immunotherapy (TDOI) to become a cornerstone in the treatment of cancer VISION To deliver transformational results for patients across cancers using tumor directed oncolytic immunotherapy to induce a powerful and durable systemic anti-tumor immune response resulting in quality survival and a chance for a cure THANK YOU